Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study
Authors:
Open Access
- 25 March 2024
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 237, 71-78
Abstract
No abstract availableKeywords
Funding Information
- Santé
- McGill University
- Canadian Institutes of Health Research (PJT-165954)
This publication has 41 references indexed in Scilit:
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational StudiesDrug Safety, 2019
- Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial FibrillationJAMA Cardiology, 2018
- Rationale, design, and preliminary results of the Quebec Warfarin Cohort StudyClinical Cardiology, 2018
- An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamicsThe Journal of Clinical Pharmacology, 2015
- Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic ImpairmentClinical Pharmacokinetics, 2013
- Coagulation disorders and hemostasis in liver diseaseHepatology, 2006
- Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial FibrillationJAMA, 2005
- Channeling bias in the interpretation of drug effectsStatistics in Medicine, 1991
- Flexible regression models with cubic splinesStatistics in Medicine, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986